Monitor the AUVELITY Alzheimer's disease agitation launch in June 2026 for prescription trends and payer uptake — this is the primary catalyst. The widening net loss and cash burn rate (~$18M/quarter) suggest the company may need to raise capital within 12-18 months if operating losses don't narrow. The NDA acceptance decision for AXS-12 is the next binary event.
Price Chart
Executive Summary
Axsome reported Q1 2026 revenue of $191.2M (+57% YoY), slightly above the $190.7M consensus, but net loss widened to -$64.5M (-$1.26/sh) vs -$59.4M (-$1.22/sh) a year ago, missing the -$0.85 EPS consensus. The quarter was highlighted by the FDA approval of AUVELITY for Alzheimer's disease agitation (April 2026) and the NDA submission for AXS-12 in narcolepsy, but the widening loss and lack of formal financial guidance temper the positive news. The stock will likely trade on the AUVELITY Alzheimer's launch potential (June 2026) offset by the cash burn trajectory.
Key Financial Metrics
Key Facts
- Q1 2026 total net product revenue of $191.2M, up 57% YoY from $121.5M
- AUVELITY net sales of $153.2M (+59% YoY); SUNOSI $33.9M (+34%); SYMBRAVO $4.1M
- Net loss widened to -$64.5M (-$1.26/sh) from -$59.4M (-$1.22/sh) in Q1 2025
- EPS of -$1.26 missed the -$0.85 consensus estimate
- Cash and equivalents $305.1M at March 31, 2026, down from $322.9M at Dec 31, 2025
- FDA approved AUVELITY for Alzheimer's disease agitation in April 2026; commercial launch on track for June 2026
- NDA for AXS-12 (narcolepsy/cataplexy) submitted to FDA
- SG&A expenses surged 53% to $185.0M, driven by pre-launch and commercialization costs
- No formal financial guidance provided; company states cash sufficient to reach cash flow positivity
- Sales force expanded to ~630 representatives for AUVELITY; SYMBRAVO sales force expanding to 150
Financial Impact
Revenue beat consensus by ~$0.5M but EPS missed by -$0.41; net loss widened by $5.1M YoY; cash burn of ~$17.8M in Q1
Risk Factors
- Cash burn of ~$18M/quarter with no path to profitability visible; potential need for dilutive financing
- SG&A spending growing faster than revenue (53% vs 57%), pressuring margins
- AUVELITY Alzheimer's launch execution risk — payer coverage and prescriber adoption uncertain
- No formal financial guidance provided, creating uncertainty around future trajectory
- Heavy reliance on AUVELITY (80% of revenue) for growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202506 |
| Document: axsm-20260504.htm | 0001193125-26-202506 |
| Document: axsm-ex99_2.htm | 0001193125-26-202506 |
| Document: 0001193125-26-202506-index-headers.html | 0001193125-26-202506 |
| Document: 0001193125-26-202506-index.html | 0001193125-26-202506 |
| Document: 0001193125-26-202506.txt | 0001193125-26-202506 |
| 8-K Data (Synthetic) | 0001193125-26-202506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access